SignalCorporate

Halozyme Therapeutics (HALO) Is Up 24.9% After Raising 2026 Revenue Outlook and Boosting Buybacks

HALO's 24.9% surge driven by raised 2026 revenue outlook and increased buybacks.

What changed

HALO's 24.9% surge driven by raised 2026 revenue outlook and increased buybacks.

Why it matters

HALO's 24.9% surge driven by raised 2026 revenue outlook and increased buybacks. — impact context not separately stored; see What changed.

Sources